Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection

This study is currently recruiting participants.
Verified March 2014 by Gilead Sciences
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01651403
First received: July 25, 2012
Last updated: March 28, 2014
Last verified: March 2014

July 25, 2012
March 28, 2014
September 2012
May 2016   (final data collection date for primary outcome measure)
Proportion of patients with serum HBV DNA < 400 copies/mL at week 72 [ Time Frame: Week 72 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01651403 on ClinicalTrials.gov Archive Site
  • Proportion of patients with hepatitis B e antigen (HBeAg) seroconversion at Week 72 [ Time Frame: Week 72 ] [ Designated as safety issue: No ]
  • Cumulative Incidence of at least 4% decrease from baseline in bone mineral density of lumbar spine [ Time Frame: Week 72 ] [ Designated as safety issue: Yes ]
  • Percent change from baseline in bone mineral density of lumbar spine [ Time Frame: Week 72 ] [ Designated as safety issue: Yes ]
  • Safety and Tolerability of Therapy [ Time Frame: Up to Week 192 ] [ Designated as safety issue: Yes ]
    Safety and tolerability is measured by the frequency of laboratory abnormalities reported as adverse events.
  • Biochemical and serological responses [ Time Frame: Week 72 ] [ Designated as safety issue: No ]
    Biochemical and serological responses as measured by normal/normalization of ALT, proportion of subjects with HBV DNA < 400 copies/mL and normal ALT, proportion of subjects with HBV DNA < 169 copies/mL, proportion of subjects with HBsAg loss and seroconversion
  • Viral Resistance [ Time Frame: Weeks 72, 144, 192 or Early Discontinuation ] [ Designated as safety issue: No ]
    Genotypic changes from baseline within the HBV polymerase for patients who were viremic (HBV DNA > or equal 400 copies/mL) with confirmed virologic breakthrough
  • Proportion of patients with HBeAg seroconversion at week 72 [ Time Frame: Week 72 ] [ Designated as safety issue: No ]
  • Cumulative Incidence of at least 4% decrease from baseline in bone mineral density of lumbar spine [ Time Frame: Week 72 ] [ Designated as safety issue: Yes ]
  • Percent change from baseline in bone mineral density of lumbar spine [ Time Frame: Week 72 ] [ Designated as safety issue: Yes ]
  • Safety and Tolerability of Therapy [ Time Frame: Up to Week 192 ] [ Designated as safety issue: Yes ]
    Safety and tolerability is measured by the frequency of laboratory abnormalities reported as adverse events.
  • Biochemical and serological responses [ Time Frame: Week 72 ] [ Designated as safety issue: No ]
    Biochemical and serological responses as measured by normal/normalization of ALT, proportion of subjects with HBV DNA < 400 copies/mL and normal ALT, proportion of subjects with HBV DNA < 169 copies/mL, proportion of subjects with HBsAg loss and seroconversion
  • Viral Resistance [ Time Frame: Weeks 72, 144, 192 or Early Discontinuation ] [ Designated as safety issue: No ]
    Genotypic changes from baseline within the HBV polymerase for patients who were viremic (HBV DNA > or equal 400 copies/mL) with confirmed virologic breakthrough
Not Provided
Not Provided
 
Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection

This placebo-controlled study evaluates the efficacy, safety and tolerability of tenofovir disoproxil fumarate (TDF) in patients 2 to <12 years old with chronic Hepatitis B infection. While studies have shown significant virologic response in adults and adolescents, the effect in children is not well established. This study will provide valuable data that can help establish the efficacy and safety profiles of TDF in children.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Chronic Hepatitis B Infection
  • Drug: Tenofovir DF

    Tenofovir disoproxil fumarate (tenofovir DF; TDF) oral tablet / oral powder

    • Subjects ≥ 17 kg: one tablet once daily (150, 200, 250 or 300 mg tablets based on body weight) or oral powder if unable to swallow a tablet.

    Other Name: Viread®
  • Drug: Tenofovir DF Placebo

    Matching placebo oral tablet / oral powder

    • Subjects ≥ 17 kg: one tablet once daily (matching of physical appearance as the corresponding active tablet) or matching oral placebo powder
    • Subjects < 17 kg and subjects ≥ 17 kg who are unable to swallow a tablet will receive once daily matching oral placebo powder
  • Experimental: Tenofovir DF
    Tenofovir disoproxil fumarate oral tablet / oral powder
    Intervention: Drug: Tenofovir DF
  • Placebo Comparator: Tenofovir DF Placebo
    Intervention: Drug: Tenofovir DF Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
March 2019
May 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or Female, 2 to < 12 years of age
  • Weight ≥ 10kg
  • Chronic HBV infection ≥ 6 months
  • HBeAg-positive or HBeAg-negative
  • HBV Viral Load ≥ 100,000 copies/mL
  • Alanin aminotransferase (ALT) ≥ 1.5 x the upper limit of the normal range (ULN) at screening
  • Creatinine Clearance ≥ 80 mL/min
  • Absolute neutrophil count (ANC) ≥ 1,500/mm^3, hemoglobin ≥ 10g/dL
  • Negative pregnancy test at screening
  • No prior tenofovir DF therapy (subjects may have received prior interferon‑alfa and/or other oral anti‑HBV nucleoside/nucleotide therapy; subjects must have discontinued interferon-alfa therapy ≥ 6 months prior to screening; subjects experienced on other anti-HBV nucleoside/nucleotide therapy must have discontinued therapy ≥ 16 weeks prior to screening to avoid flare if randomized to the placebo arm)

Exclusion Criteria:

  • Pregnant or lactating
  • Decompensated liver disease
  • Received interferon therapy within 6 months of Screening
  • Received anti-HBV nucleoside/nucleotide therapy within 16 weeks of Screening
  • Alpha-fetoprotein levels > 50 ng/mL
  • Evidence of hepatocellular carcinoma (HCC)
  • Co-infection with HIV, acute hepatitis A virus (HAV), hepatitis C virus (HCV), or hepatitis D virus (HDV)
  • Chronic liver disease not due to HBV
  • History of significant renal, cardiovascular, pulmonary, neurological or bone disease
  • Long term non-steroidal, anti-inflammatory drug therapy
Both
2 Years to 11 Years
No
Contact: Yvonne Walker yvonne.walker@gilead.com
United States,   Bulgaria,   India,   Korea, Republic of,   Poland,   Romania,   Taiwan
 
NCT01651403
GS-US-174-0144
Yes
Gilead Sciences
Gilead Sciences
Not Provided
Study Director: Bittoo Kanwar, MD Gilead Sciences
Gilead Sciences
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP